03 Aug 2015

VIMOVO modified-release (Naproxen / Esomeprazole) - United Kingdom

ATC: M01AE
MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
PROPIONIC ACID DERIVATIVES
VIMOVO modified-release tablets

Last Updated on 03 Aug 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

VIMOVO modified-release tablets Indication

VIMOVO is indicated in adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.

 

VIMOVO modified-release tablets Generic Name

Naproxen / Esomeprazole

Type

POM

Summary Product Characteristics (SPCs) Links
SPC - VIMOVO 500 mg/20 mg modified-release tablets (external site)

Related Learning Zones

COPD Knowledge Centre

COPD Knowledge Centre

The COPD Knowledge Centre has been designed to provide healthcare professionals with free access to educational materials and disease awareness information. This includes information on the epidemiology, pathophysiology and symptoms of COPD and the latest guidelines for the diagnosis, treatment and management of the disease.

COPD-specific resources such as videosguidelinesinfographics, materials for your patients, upcoming events, useful websites and symposium videos and materials from ATS 2014 and ATS 2015 are available free of charge.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

Cystic fibrosis (CF) is a genetic condition caused by a defect in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. The Cystic Fibrosis Knowledge Centre provides healthcare professionals with access to disease awareness information, emerging and established treatment options and current best practice based on recently updated guidelines by the European Cystic Fibrosis Society (ECFS). A resources section contains external links to upcoming medical conferences and patient support groups.

This resource is developed by EPG Health Media for epgonline.org, supported by an independent educational grant from Vertex.

VIMOVO modified-release Marketing Information

VIMOVO modified-release Generic Name
Naproxen / Esomeprazole
Marketing Company
AstraZeneca UK Ltd
Drug Type
POM
Date of Issue, Marketing Authority 05/11/2010

Related Drugs - Rheumatology

Back to top